Hospital Injectable Drugs Market Report
Hospital Injectable Drugs Market, By Type (Generic Sterile Injectables, Sterile Intravenous (IV) Solutions), Application (Cardiology & Metabolic disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Infectious Diseases, and Others), End-User (Hospital Pharmacy, Retail Pharmacy, E-commerce), and Region - COVID-19 Impact Analysis and Forecast to 2026.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Hospital Injectable Drugs market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
Hospital Injectable Drugs Market, By Type (Generic Sterile Injectables, Sterile Intravenous (IV) Solutions), Application (Cardiology & Metabolic disorders, Neurology, Oncology, Autoimmune, Gastroenterology, Hematology, Infectious Diseases, and Others), End-User ...
Impact of COVID-19 on Hospital Injectable Drugs Market
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Hospital Injectable Drugs Market is projected to grow from USD 38.7 billion in 2020 to USD 51.4 billion by 2026 at a CAGR of around 4.8% during the forecast period.
Hospital injectable drugs can be defined as the medications which are introduced into the patient’s body with the help of injections. These drugs are injected directly into the bloodstream with the help of injectable devices such as syringes and needles.
Key players operating in the Hospital Injectable Drugs market are-
The growth of the hospital injectable drugs market is primarily driven by an increasing number of people suffering from chronic diseases and accidental injuries. Expanding the geriatric populace across geographies is expected to drive market growth at a significant rate during the review period. In addition to this, increasing investment in research and development activities to develop advanced healthcare solutions is likely to create lucrative opportunities for the players operating in the global hospital injectable drugs market in the coming years.
By end-user, the hospital injectable drugs market has been bifurcated into hospital pharmacy, retail pharmacy, and e-commerce. The hospital pharmacy segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the convenience and easy availability of required drugs.
By region, the North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to the high adoption rate of advanced diagnostic equipment coupled with the presence of key market players such as Kemper Medical, Inc. (US) and Chemyx, Inc. (US). The market growth in Asia-Pacific is expected to be driven by the increasing adoption of Hospital Injectable Drugs in diagnostic procedures, particularly in developing countries.
The covid-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the hospital injectable drugs market negatively as the healthcare solutions other than covid-19 treatment declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of lockdown affected the product availability on time and thus, affected the market growth.
Here is the list of the group of customers that the hospital inhjectable drugs market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at firstname.lastname@example.org.
The hospital injectable drugs market is expected to witness an impressive growth of 4.8% CAGR in the coming years.
Baxter International Inc. (US), Sanofi S.A. (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AstraZeneca plc (UK), Gilead Sciences, Inc. (US), Merck & Co., Inc. (US), Novartis International AG (Switzerland), Johnson & Johnson (US) and Novo Nordisk A/S (Denmark) are among the key players in the hospital injectable drugs market.
The hospital injectable drugs market size is expected to reach USD 51.4 billion in the foreseeable future.
The hospital pharmacy segment is expected to register significant growth in the hospital injectable drugs market in the coming years.
North America accounted for the largest share in the hospital injectable drugs market in 2020.
Hospital injectable drugs distributors, Hospital injectable drugs suppliers, Hospital injectable drugs manufacturers, Logistics organizations, Government bodies are the target audience in the hospital injectable drugs market.